Trials / Completed
CompletedNCT00213993
Topical Antiperspirant for Hand-Foot Syndrome
Topical Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Associated With Capecitabine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- University of Wisconsin, Madison · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | antiperspirant | antiperspirant topically once daily to one foot |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2006-10-01
- Completion
- 2007-01-01
- First posted
- 2005-09-21
- Last updated
- 2015-10-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00213993. Inclusion in this directory is not an endorsement.